Zydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha will be available in 100 mg and 40 mg dosages. The prices are significantly lower than the reference drug. This launch expands access to immuno-oncology therapies. The company aims to support patients with consistent care.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mgIh9iF
via IFTTT
No comments:
Post a Comment